JavaScript 似乎在您的浏览器中禁用。 在我们的网站上获得最佳体验，请务必打开 Javascript 在您的浏览器。

为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验，建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?)，感谢您选择我们！

切换导航

我的购物车

搜索

托法替尼

强大的细胞渗透性\ xa0Janus激酶（JAK）抑制剂

规格或纯度: ≥98% (HPLC)

CAS编号: 477600-75-2
分子式: C₁₆H₂₀N₆O
分子量: 312.37
MDL号: MFCD11616529
PubChem编号: 9926791

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货	价格	数量
T122330-5mg	5mg	现货
T122330-25mg	25mg	现货
T122330-100mg	100mg	现货
T122330-500mg	500mg	现货
T122330-1g	1g	现货

查看相关系列

Janus kinase 1 Inhibitor Janus kinase 2 Inhibitor Janus kinase 3 Inhibitor protein kinase N1 Inhibitor tyrosine kinase 2 Inhibitor

Skip to the end of the images gallery

main product photo

Skip to the beginning of the images gallery

基本描述

英文别名	1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YLAMINO)-.BETA.-OXO-, (3R,4R)- \| NSC782351 \| NSC-782351 \| 1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YLAMINO)-beta-OXO-, (3R,4R)- \| 4oti \| Tasocit
规格或纯度	≥98% (HPLC)
英文名称	Tofacitinib
生化机理	托法替尼(Tofacitinib) 是一种强效Janus激酶3（JAK3）抑制剂，而且还带有一些JAK-1抑制活性。它会阻止下游STAT信号导致强效抑制炎性细胞因子产生的免疫抑制和抗炎活性。托法替尼(Tofacitinib)正在研究用于一些自身免疫性疾病包括类风湿关节炎，银屑病和干眼症的治疗。具有某些JAK1抑制活性的有力的，细胞可渗透的詹纳斯激酶3（JAK3）抑制剂。吡咯并[2,3-d]嘧啶衍生物。阻断下游STAT信号传导，从而有效抑制炎症因子并产生免疫抑制。
储存温度	-20°C储存
运输条件	超低温冰袋运输
备注	如果有可能，您尽量在使用的当天配置溶液，并在当天使用完它。但是，如果您需要预先配制储备溶液，我们建议您将溶液等份保存在-20°C的密封小瓶中。通常，它们最多可以使用一个月。在使用前和打开样品瓶之前，我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度，用法和处理的建议吗？请访问我们的常见问题（FAQ）页面以获取更多详细信息。

名称和标识符

IUPAC Name	3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
INCHI	InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1
InChi Key	UJLAWZDWDVHWOW-YPMHNXCESA-N
Canonical SMILES	CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N
Isomeric SMILES	C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N
WGK Germany	3
PubChem CID	9926791
分子量	312.37

数据库链接

CAS Registry No.	477600-75-2
Wikipedia	Tofacitinib
DiscoveRx TREEspot	CP-690550\|
PubChem CID	9926791
ChEMBL Ligand	CHEMBL221959
RCSB PDB Ligand	MI1
PEP	tofacitinib
Reactome Reaction	R-HSA-9678737, R-HSA-9678935, R-HSA-9678561, R-HSA-9679028
Reactome Drug	R-ALL-9678779
DrugCentral Ligand	4713

安全和危险性（GHS）

象形图	Toxic Health Hazard Harmful
信号词	Danger
危险声明	H315: Causes skin irritation H319: Causes serious eye irritation H335: May cause respiratory irritation H301: Toxic if swallowed H311: Toxic in contact with skin H331: Toxic if inhaled H351: Suspected of causing cancer H373: Causes damage to organs through prolonged or repeated exposure H302: Harmful if swallowed H360: May damage fertility or the unborn child H360Df: May damage the unborn child; Suspected of damaging fertility
预防措施声明	P261,P305+P351+P338,P280,P302+P352,P321,P405,P501,P264,P260,P271,P270,P304+P340,P403+P233,P362+P364,P330,P361+P364,P203,P264+P265,P301+P316,P301+P317,P318,P337+P317,P332+P317,P316,P319
WGK Germany	3

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

相关文档

质检报告COA

请输入批号:

SDS中文版 SDS英文版

质量技术规格说明书

产品问答

产品问答

登录提交问题

您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH et al.. (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.. Science, 302 (5646): (875-8). [PMID:14593182]
2. Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, Shang-Poa C, Doty JL, Elliott EA, Fisher MB, Hines M et al.. (2010) Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.. J Med Chem, 53 (24): (8468-84). [PMID:21105711]
3. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M et al.. (2011) Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).. J Immunol, 186 (7): (4234-43). [PMID:21383241]
4. Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG et al.. (2017) Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.. Gut, 66 (6): (1049-1059). [PMID:28209624]
5. Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W et al.. (2017) Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.. N Engl J Med, 376 (18): (1723-1736). [PMID:28467869]
6. Clark JD, Flanagan ME, Telliez JB. (2014) Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.. J Med Chem, 57 (12): (5023-38). [PMID:24417533]
7. Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, Chen JC, Cerise JE, Jabbari A, Winge MC et al.. (2016) Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.. JCI Insight, 1 (15): (e89776). [PMID:27699252]
8. Ostrovskyi D, Rumpf T, Eib J, Lumbroso A, Slynko I, Klaeger S, Heinzlmeir S, Forster M, Gehringer M, Pfaffenrot E et al.. (2016) Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).. Future Med Chem, 8 (13): (1537-51). [PMID:27572962]
9. Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S et al.. (2018) Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.. J Crohns Colitis, 12 (2): (145-156). [PMID:29028981]
10. Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi I et al.. (2018) Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies.. Intest Res, 16 (2): (233-245). [PMID:29743836]

上海阿拉丁生化科技股份有限公司

销售条款及条件隐私政策

© 2016 ALADDIN-E.COM . 版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任

沪公网安备 31012002004058号沪ICP备09093490号-2

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。

危险品化学品经营许可证（带存储）

营业执照(三证合一)